|
Variable
|
DNA-PCR result
|
p value
|
Crude OR (95 % CI)
|
Adjusted OR (95 % CI)
|
|---|
|
Positive (%)
|
Negative (%)
|
|---|
|
Sex
| | |
0.992
| | |
|
Male
|
14 (4.3)
|
309 (95.7)
|
0.992
|
1.00 (0.46–2.17)
| |
|
Female
|
13 (4.3)
|
288 (95.7)
| |
Ref
| |
|
Place of birth
| | |
0.016
| | |
|
Health facility
|
19 (3.6)
|
506 (96.4)
| |
Ref
|
Ref
|
|
Home
|
6 (10.9)
|
49 (89.1)
| |
3.26 (1.24–8.53)
|
3.10 (0.53–18.24)
|
|
Type of feeding
| | |
0.104
| | |
|
Exclusive BF
|
16 (3.2)
|
478 (96.8)
| |
Ref
| |
|
Exclusive RF
|
6 (6.5)
|
85 (93.5)
| |
2.11 (0.80–5.54)
| |
|
Mixed feeding
|
3 (6.9)
|
28 (93.1)
| |
0.66 (0.16–2.81)
| |
|
Infant PMTCT
| | |
0.000a
|
–
| |
|
Sdb NVP or none
|
13 (11.2)
|
103 (88.8)
| | | |
|
Sd NVP + AZT
|
11 (3.9)
|
268 (96.1)
| | | |
|
Sd NVP ≥6 weeks
|
0 (0)
|
191 (100)
| | | |
|
Mother CD4 during pregnancy
| | |
0.033
| | |
|
<100/mm3
|
3 (17.6)
|
14 (82.4)
| |
5.68 (1.15–28.05)
|
4.50 (0.71–28.56)
|
|
100–500/mm3
|
3 (1.3)
|
236 (98.7)
| |
0.34 (0.08–1.53)
|
0.26 (0.05–1.33)
|
|
>500/mm3
|
4 (3.6)
|
106 (96.4)
| |
Ref
|
Ref
|
|
Mother WHO stage
| | |
0.344
| | |
|
WHO stage 1
|
7 (3.3)
|
204 (96.7)
| |
Ref
| |
|
WHO stage 2
|
2 (2.1)
|
91 (97.9)
| |
0.64 (0.13–3.14)
| |
|
WHO stage 3/4
|
6 (6)
|
93 (94)
| |
1.88 (0.62–5.75)
| |
|
Mother any PMTCT
| | |
0.000
| | |
|
No
|
13 (12.7)
|
89 (87.3)
| |
6.10 (2.45–15.17)
|
3.80 (0.68–21.09)
|
|
Yes
|
8 (2.3)
|
334 (97.7)
| |
Ref
|
Ref
|
|
Type of PMTCT (mother)
| | |
0.402
| | |
|
AZT only
|
2 (4)
|
48 (96)
| |
2.01 (0.39–10.24)
| |
|
HAART
|
6 (2)
|
289 (98)
| |
Ref
| |
|
Antenatal care follow up
| | |
0.000
| | |
|
No
|
11 (12.8)
|
75 (87.2)
| |
5.54 (2.27–13.52)
|
4.05 (0.25–65.75)
|
|
Yes
|
10 (2.6)
|
378 (97.4)
| |
Ref
|
Ref
|
|
Mother care and treatment
| | |
0.003
| | |
|
Enrolled in care and Rxc
|
14 (3.3)
|
406 (96.7)
| |
Ref
|
–
|
|
Not enrolled
|
7 (13)
|
47 (87)
| |
4.32 (1.66–11.24)
| |
-
a
X
2 test was used
-
bSingle dose
-
cTreatment
